StemCell Therapy

Market Study Report LLC adds a latest research study on Regenerative Medicine market Statistics for 2020-2026, which is a detailed analysis of this business space inclusive of trends, competitive landscape, and the market size. Encompassing one or more parameters among product analysis, application potential, and the regional growth landscape, Regenerative Medicine market also includes an in-depth study of the industry's competitive scenario.

The latest research report of the Regenerative Medicine market provides a comprehensive assessment of the key factors driving the industry growth. The study lists out the existing challenges and opportunities crucial to business expansion in the upcoming years. It also houses an economy-wide database to enhance business management and boasts of a dedicated section for profiling leading players. In addition, impact assessment of the COVID-19 pandemic is covered as well.

Request a sample Report of Regenerative Medicine Market at:https://www.marketstudyreport.com/request-a-sample/2957730?utm_source=decresearch.com&utm_medium=AK

Main pointers from the COVDI-19 impact analysis:

Additional highlights of the Regenerative Medicine market report:

Ask for Discount on Regenerative Medicine Market Report at:https://www.marketstudyreport.com/check-for-discount/2957730?utm_source=decresearch.com&utm_medium=AK

An outline of the regional analysis:

Comprehensive assessment of all opportunities and risks in the Regenerative Medicine market.

This exclusive study addresses key questions for stakeholders in the Regenerative Medicine Market:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-regenerative-medicine-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

1. Global Albumin Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-albumin-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Dental Supplies Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-dental-supplies-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/automotive-glazing-market-growth-size-share-demand-trends-and-forecasts-to-2027-2020-10-08

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

More:
Regenerative Medicine Market by Type, Application, Element - Global Trends and Forecast to 2026 - News by Decresearch

The Global Regenerative Medicine Market research report is a comprehensive study of the Regenerative Medicine industry and its prospects. The global Regenerative Medicine Market was valued at US$ 13.56 Mn in 2018 and is expected to reach US$ 55.67 Mn Mn by 2026, expanding at a CAGR of 23% during the forecast period.

The global Regenerative Medicine market has been subjected to several regulatory compliances and crucial coding terminology over the years. Adherence to regulatory standards remains crucial for vendors.

The study considers the present scenario of the Regenerative Medicine market and its market dynamics for the period 20202026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report covers both the demand and supply aspect of the market. This research report on the Regenerative Medicine market covers sizing and forecast, market share, industry trends, growth drivers, and vendor analysis.

Browse Full Research report along with TOC, Tables & Figures: https://www.alltheresearch.com/report/232/Regenerative Medicine

The study profiles and examines leading companies and other prominent companies operating in the Regenerative Medicine industry.

List of key players profiled in the report:

Regenerative Medicine Market segmentation as per below:

Product Types:

Applications:

Request for Sample Copy of Report to get more information about the market @ https://www.alltheresearch.com/sample-request/232

COVID-19 Impact on Regenerative Medicine Industry

The outbreak of COVID-19 has bought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Regenerative Medicine market. Overall competitive landscape and market dynamics of Regenerative Medicine has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Regenerative Medicine market.

The competitive environment in the Regenerative Medicine market is intensifying. The market currently witnesses the presence of several major as well as other prominent vendors, contributing toward the market growth. However, the market is observing an influx of local vendors entering the market.

Request COVID19 Impact Analysis on Regenerative Medicine Industry Sample Report @ https://www.alltheresearch.com/impactC19-request/232

Vendors can consider targeting key regions such as APAC, North America, and Europe to gather maximum customer attention. Countries in the APAC region such as China, India, and Japan among others are expected to display significant growth prospects in the future due to high economic growth forecasts along with huge population statistics leading to high consumption of goods and products.

Regional Overview & Analysis of Regenerative Medicine Market:

North America(US and Canada)

Europe(UK, Germany, France and Rest of Europe)

Asia Pacific(China, Japan, India and Rest of Asia Pacific)

Latin America(Brazil, Mexico and Rest of Latin America)

Middle East & Africa(GCC and Rest of Middle East & Africa)

The changing regulatory compliance scenario and the growing purchasing power among consumers are likely to promise well for the North America market. New product development and technological advancements remain key for competitors to capitalize upon in the Regenerative Medicine industry across the globe.

Report Snapshot:

Report Coverage

Details

Base Year:

2018

Historical Data for:

2014 to 2018

Forecast Period:

2020 to2026

Market Size in 2018:

USD 13.56 Mn

Forecast Period 2020 to 2026 CAGR:

23%

2026 Value Projection:

USD 55.67 Mn

Ask for more details or request custom reports from our industry experts at @ https://www.alltheresearch.com/customization/232

Key Market Insights:

Read this article:
Regenerative Medicine Market Analysis and In-depth Research on Size, Trends, Emerging Growth Factors and Forecasts 2026 - PRnews Leader

What is Adipose Tissue Derived Stem Cell Therapy?

Adipose tissue derived stem cells (ADSCs) are stem cells originated from adipocytes. ADSCs have characteristics similar to bone marrow mesenchymal stem cells. Thus Adipose-derived stem cells substitute for bone marrow as a source of stem cells. Different varieties of manual and automatic stem cell separation procedures are used to separate adipose stem cells (ASCs) from adipose tissue. Flow cytometry can be utilized to isolate ADSCs from other stem cells within a cell solution. Currently, adipose derived stem cells (ADSCs) are generally used in the generation of regenerative medicine due to its anti-inflammatory, anti-apoptotic, and immunomodulatory properties.

Download PDF Sample Report Here @ https://www.theinsightpartners.com/sample/TIPRE00014843/

The research provides answers to the following key questions:

A new market study report by The Insight Partners on the Adipose Tissue Derived Stem Cell Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets. Some of the key players in the study are AlloCure, Inc, Antria, Inc., Celgene Corporation, Cellleris SA, Corestem, Inc., Cytori Therapeutics, LLC, Intrexon, Inc., Mesoblast Ltd., Pluristem Therapeutics, Inc., Tissue Genesis, Inc. etc.

Market Insights:

The Adipose Tissue-derived Stem Cell Therapy Market is growing due to increasing use of regenerative medicine in disease treatment and increasing private and public funding for stem cell therapy. However, high cost associated with stem cell processing hampers growth of this market.

An Overview of the Impact of COVID-19 on this Market:

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Adipose Tissue Derived Stem Cell Therapy Market which would mention How the Covid-19 is Affecting the Adipose Tissue Derived Stem Cell Therapy Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Adipose Tissue Derived Stem Cell Therapy Players to fight Covid-19 Impact.

Adipose Tissue Derived Stem Cell Therapy Market: Regional analysis includes:

The Adipose Tissue Derived Stem Cell Therapy Market segments and Market Data Break Down are illuminated below:By Cell Type (Autologous Stem Cells, Allogeneic Stem Cells);

Product (Cell Line, Culture Media);

Disease (Cancer, Obesity, Wounds and Injuries, Musculoskeletal Diseases, Cardiovascular Diseases, Others);

End User (Hospitals and Trauma Centers, Cell banks and Tissue Banks, Research Laboratories and Academic Institutes, Others)

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Adipose Tissue Derived Stem Cell Therapy market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal with regard to different segments. The report predicts the influence of different industry aspects on the Adipose Tissue Derived Stem Cell Therapy market segments and regions.

This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Adipose Tissue Derived Stem Cell Therapy market.

Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure @ https://www.theinsightpartners.com/buy/TIPRE00014843/

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 10+ companies.

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Link:
Adipose Tissue Derived Stem Cell Therapy Market to Set Phenomenal Growth in Key Regions by 2027 | AlloCure, Inc, Antria, Inc., Cellleris SA, Tissue...

SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Dr. Sean M. Anderson, founder of Aqua Regenerative Therapies and the scientist behind the creation of the world's first and only brain regenerating biomaterial at UCLA, has launched a patented skin care product under the brand name NeuLuna. Focusing his expertise on the skin, Dr. Anderson formulated a skin cream that improves skin adsorption of hyaluronic acid by 250%.

Sold online at neuluna.com, NeuLuna leads to softer, smoother skin in a matter of days. Customers have reported that the product helps with acne and acne scars, eye bags and wrinkles, dry skin, hands, and elbows, sun spots, rosacea, and eczema.

"It helps keep my skin firm and smooth, and even helps heal some nicks and scratches faster. It also helps prevent acne, from what I have noticed. My skin has never felt smoother and better. I highly recommend this product!" said customer Hazel F.

"The product is truly unique in the skin care space. With an issued patent covering the core technology of the product, this product is not available anywhere else. And we hope this helps us achieve our goal of funding our regenerative medicine research," said Dr. Anderson.

Sales from the skin care product directly fund Dr. Anderson's research. Currently, his interests center on developing treatments for stroke, traumatic brain and spinal cord injury, heart disease, pulmonary disease, wound healing, and diabetes, particularly diabetic neuropathy. More information can be found at aquabiomaterials.com.

Contact Dr. Sean M. Anderson at [emailprotected] for more information.

SOURCE Aqua Regenerative Therapies

https://www.aquabiomaterials.com

Link:
Creator of Brain Regenerating Biomaterial Launches Patented Skin Care Product - PRNewswire

Regenerative Medicine Market report would come handy to understand the competitors in the market and give an insight into sales, volumes, revenues in the Regenerative Medicine Industry & will also assists in making strategic decisions. The report also helps to decide corporate product & marketing strategies. It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the Regenerative Medicine industry. Both established and new players in Regenerative Medicine industries can use the report to understand the Regenerative Medicine market.

In Global Market, the Following Companies Are Covered:

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14857372

Analysis of the Market:

Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function. It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the bodys innate healing ability in order to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases.

Currently, some companies in the world can provide regenerative medicine service, mainly concentrating in USA. The main market players are DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, etc.

USA is the largest market of regenerative medicine, which occupies 51.09 percent of global regenerative medicine market share in 2015. It is followed by EU, which has around 16.66 percent of the global total industry. Other main regions which take important part in this industry include Japan and China.

According to the research, the most potential market in the main countries of regenerative medicine industry is Asia, determined by the rising level of medical care. Besides, South America, Middle East should also be focused by the investors. They are the potential consumers of regenerative medicine.

Despite the presence of competition problems, due to the huge industry profits, investors are still optimistic about this area; there will be more investments to enter the field.

The relatively-mature technology is cell transplantation; tissue engineering and therapeutic cloning has its technical advantages, which is the direction of future research and development.

Market Analysis and Insights: Global Regenerative Medicine Market

In 2019, the global Regenerative Medicine market size was USUSD 8298.8 million and it is expected to reach USUSD 36710 million by the end of 2026, with a CAGR of 23.4% during 2021-2026.

Global Regenerative Medicine Scope and Market Size

Regenerative Medicine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Regenerative Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Regenerative Medicine market is segmented into Cell Therapy, Tissue Engineering, Biomaterial, Other, etc.

Segment by Application, the Regenerative Medicine market is segmented into Dermatology, Cardiovascular, CNS, Orthopedic, Others, etc.

Regional and Country-level Analysis

The Regenerative Medicine market is analysed and market size information is provided by regions (countries).

The key regions covered in the Regenerative Medicine market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape and Regenerative Medicine Market Share Analysis

Regenerative Medicine market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Regenerative Medicine business, the date to enter into the Regenerative Medicine market, Regenerative Medicine product introduction, recent developments, etc.

The major vendors include DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologies, Bellicum Pharmaceuticals, etc.

This report focuses on the global Regenerative Medicine status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Regenerative Medicine development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

Regenerative Medicine Market Breakdown by Types:

s

Regenerative Medicine Market Breakdown by Application:

Critical highlights covered in the Global Regenerative Medicine market include:

The information available in the Regenerative Medicine Market report is segmented for proper understanding. The Table of contents contains Market outline, Market characteristics, Market segmentation analysis, Market sizing, customer landscape & Regional landscape. For further improving the understand ability various exhibits (Tabular Data & Pie Charts) has also been used in the Regenerative Medicine Market report.

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14857372

Reasons for Buy Regenerative Medicine Market Report:

In the end, Regenerative Medicine Industry report provides the main region, market conditions with the product price,profit, capacity, production, supply, demand and market growth rateand forecast etc. This report also Present newproject SWOT analysis,investment feasibility analysis, andinvestment return analysis.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +14242530807 / + 44 20 3239 8187

Global Konjac Gum Market 2020 Industry Analysis, Size, Share, Trends, Market Demand, Growth, Opportunities and Showing Impressive Growth by 2026

Global MEMS G Meter Market 2020 Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Showing Impressive Growth by 2024

Blockchain Market Size, News andlargeGrowth With Regional Trends By Forecast 2026 Research Reportwith the guide of360marketupdates

Global Algae Feed Market Size in 2020 Industry Demand, Market Share, Trend, Industry News, Business Growth, Top Key Players, Showing Impressive Growth by 2026

Account Based Market Size, Growth Opportunities, Emerging Technologies, Trends,Growth, Segments, Landscape and Research Reportwith the guide of360marketupdates

See the article here:
Regenerative Medicine Market anticipates revenue will hit up to XX% CAGR by 2026: Covering Market Share, Market Segmentation (by Major Players, Type,...

New York, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Amniotic Membrane Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Enzyme ; Application ; End User, Country" - https://www.reportlinker.com/p05978887/?utm_source=GNW However, limitations encountered while using amniotic membranes in emerging nations are expected to obstruct the growth of the market to a certain extent during the forecast years.

The amniotic membrane is the innermost fetal layer, lining the amniotic cavity and protecting the fetus during pregnancy.The outer layer, termed chorionic membrane, further separates the fetus from maternal tissues.

Various researches focusing on the physiological functions of fetal layers have shown that amniotic membrane not only provides physical support for the fetus but also serves as a metabolically active filter through direct interaction with amniotic fluid. The translucent, avascular, low immunogenic, anti-inflammatory, anti-scarring, and wound healing properties of amniotic membrane allow this material function beyond its role in vivo and assume a wide range of applications in regenerative medicine.

The clinical use of amniotic membrane has a long history, with the first reports on its application in the treatment of skin burns and wounds more than a century ago.These ground-breaking studies played a significant role in advancing the use of an amniotic membrane in surgery, especially in areas such as the reconstruction of the corneal and conjunctival surfaces, treatment of open ulcers and traumatic wounds, and skin transplantation.

In parallel, the shelf life of the amniotic membrane has been extended by irradiation, air-drying, lyophilization, cryo-preservation, and glycerol preservation techniques. These methods are expected to further expand the use of an amniotic membrane in ophthalmology to treat corneal, conjunctival and limbal lesions, burns, scars and defects as well as general surgery to reconstruct the skin, genitourinary tract and other surfaces.

Amniotic membranes also appear to have natural protective and reparative functions; they may also be used for efficient delivery of specific factors to enhance the protection or repair of damaged tissue through genetic modification.

Based on enzyme, the amniotic membrane market, by enzyme, is segmented into cryopreserved amniotic membrane, and dehydrated amniotic membrane. The cryopreserved amniotic membrane segment held the largest share of the market in 2019, whereas the dehydrated amniotic membrane segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on application, the amniotic membrane market, by application, is segmented into surgical wounds, ophthalmology, and others. The surgical wounds segment held the largest share of the market in 2019, also the segment is anticipated to register the highest CAGR in the market during the forecast period...Based on end-user, the amniotic membrane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, research institute and academic institutes.The hospitals segment held the largest share of the market in 2019.

Moreover, the ambulatory surgical centers segment is estimated to register the highest CAGR in the market during the forecast period.

Some of the major primary and secondary sources for amniotic membranes market included in the report are American Society of Plastic Surgeons, Beckers Healthcare report, and others.Read the full report: https://www.reportlinker.com/p05978887/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Continued here:
The Amniotic membrane market is expected to reach US$ 1175.2million in 2027 from US$ 667.4million in 2019 - GlobeNewswire

Provost Professor Scott Fraser is recognized for developing technology that provides unprecedented views of live organisms, from embryonic development to old age. [3 min read]

Provost Professor Scott Fraser, a recognized innovator whose inventions have found wide use in both scientific and clinical settings, is an elected member of the National Academy of Medicine. (Photo: No Montes.)

Scott Fraser, Provost Professor of Biological Sciences, Biomedical Engineering, Physiology and Biophysics, Stem Cell Biology and Regenerative Medicine, Pediatrics, Radiology and Ophthalmology, has been elected to the National Academy of Medicine.

Fraser, who holds joint appointments at the USC Dornsife College of Letters, Arts and Sciences and USC Viterbi School of Engineering as well as the Elizabeth Garrett Chair in Convergent Bioscience, is one of just 90 researchers chosen from among the worlds leading scientists to become members of the academy.

Professor Scott E. Fraser is a brilliant biophysicist and innovator, said USC Provost Charles F. Zukoski. He is being recognized for groundbreaking advancements in biology and medicine. His research, which centers on imaging and molecular analyses of intact biological systems, serves as inspiration for future generations of engineers, scientists and medical professionals.

Among the reasons for his election, the academy noted Frasers work integrating biophysics, quantitative biology, and molecular imaging to enable unprecedented views of normal function and disease in live organisms, from embryonic development to old age.

Ive always been fascinated by interdisciplinary teams that can bring new insights into old problems by combining the insights from science, engineering and medicine, Fraser said.

Applying tricks from other fields

Fraser, who earned his bachelors degree in physics and his Ph.D. in biophysics, says he gravitated toward research in biology because there are so many open questions, and so many things that have been thought to be impossible to answer but tricks from other fields make the impossible possible, if the team is willing to tackle it together.

Frasers research delves into early development, organogenesis (the process by which internal organs emerge and develop) and medical diagnostics. His work has spawned several start-up companies and has been used in a number of instruments and FDA-approved diagnostics.

We keep our eyes open to translation of the work in the lab to industrial and clinical utility, he said, adding that USCs Alfred E. Mann Institute for Biomedical Engineering and USC Viterbis National Science Foundation-funded Innovation Corps node have both played key roles and offered important instruction on how to best bring their work to potential customers.

In the last year, our IP (intellectual property) has been licensed by a half-dozen different companies, he said. So, we know the work can lead to new instruments, new diagnostics and new techniques.

Fraser said his team works diligently to ensure collaborators in scientific and clinical fields also benefit from their efforts.

We have built the Translational Imaging Center on the University Park campus and the Translational Biomedical Imaging Center at Childrens Hospital Los Angeles to help support users with interests in fields ranging from regenerative medicine to cancer and diabetes. This is already empowering them to make new insights into their research challenges.

What we hope to do is to make it possible for researchers and clinicians to have aha moments, when they can see things for the first time.

A career highlighted by innovation

After earning his Ph.D. in 1979, Fraser joined the faculty at the University of California, Irvine, where he rose through the ranks to become chair of the Department of Physiology and Biophysics. In 1990, he moved to Caltech to serve as the Anna L. Rosen Professor of Biology and the director of the Biological Imaging Center. There, he served as the founding director of both the Caltech Brain Imaging Center and the Rosen Center for Biological Engineering and helped found the Kavli Nanoscience Institute.

In Fall 2012, Fraser moved to USC as Provost Professor at USC Dornsife and USC Viterbi, with formal links to Childrens Hospital Los Angeles and Keck School of Medicine of USC. He serves as the director of science initiatives for USC as well as co-director of the Bridge Institute at the USC Michelson Center for Convergent Bioscience.

A prolific author and inventor, Fraser has more than 240 peer-reviewed articles and more than 75 issued patents to his credit. He is the recipient of numerous honors and has been elected to the National Academy of Inventors, the American Institute for Medical and Biological Engineering, the American Association for the Advancement of Science, the American Academy of Arts and Sciences and the European Academy of Science.

About the National Academy of Medicine

The National Academy of Medicine, established in 1970 as the Institute of Medicine, is an independent organization of professionals from diverse fields including health and medicine, and the natural, social and behavioral sciences. Election to the academy recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

See the original post:
USC biological imaging innovator elected to National Academy of Medicine > News > USC Dornsife - USC Dornsife College of Letters, Arts and...

The report also provides an in-depth analysis of the competitive landscape and behavior of market participants. In this way, market participants can familiarize themselves with the current and future competitive scenario of the global market for Orthopedic Regenerative Medicine and take strategic initiatives to gain a competitive advantage. The market analysts have carried out extensive studies using research methods such as PESTLE and Porters Five Forces analysis. Overall, this report can prove to be a useful tool for market participants to gain deep insight into the global market for Orthopedic Regenerative Medicine and to understand the main perspectives and ways to increase their profit margins.

Free Sample Report + All Related Graphs & Charts @: https://www.coherentmarketinsights.com/insight/request-sample/3566

The MAJOR COMPANIES covered in Orthopedic Regenerative Medicine are:

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Orthopedic Regenerative Medicine manufacturing sites, capacity, production, ex-factory price, and revenue and market share in global market.

Orthopedic Regenerative Medicine Market: Segment Analysis:

The report section contains segmentations such as application, product type and end user. These segments help determine which parts of the market will improve over others. This section analysis provides information on the most important aspects of developing certain categories better than others. It helps readers understand strategies to make solid investments. The market for Orthopedic Regenerative Medicine is segmented according to product type, applications and end users.

The end users/applications and product categories analysis:

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Orthopedic Regenerative Medicine for each application, including-

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Get Up to 10-25% Discount on This Premium [emailprotected]: https://www.coherentmarketinsights.com/insight/request-discount/3566

Table of Contents

Part I Orthopedic Regenerative Medicine Industry Overview

Chapter One Orthopedic Regenerative Medicine Industry Overview

1.1 Orthopedic Regenerative Medicine Definition

1.2 Orthopedic Regenerative Medicine Classification Analysis

1.2.1 Orthopedic Regenerative Medicine Main Classification Analysis

1.2.2 Orthopedic Regenerative Medicine Main Classification Share Analysis

1.3 Orthopedic Regenerative Medicine Application Analysis

1.3.1 Orthopedic Regenerative Medicine Main Application Analysis

1.3.2 Orthopedic Regenerative Medicine Main Application Share Analysis

1.4 Orthopedic Regenerative Medicine Industry Chain Structure Analysis

1.5 Orthopedic Regenerative Medicine Industry Development Overview

1.5.1 Orthopedic Regenerative Medicine Product History Development Overview

1.5.1 Orthopedic Regenerative Medicine Product Market Development Overview

1.6 Orthopedic Regenerative Medicine Global Market Comparison Analysis

1.6.1 Orthopedic Regenerative Medicine Global Import Market Analysis

1.6.2 Orthopedic Regenerative Medicine Global Export Market Analysis

1.6.3 Orthopedic Regenerative Medicine Global Main Region Market Analysis

1.6.4 Orthopedic Regenerative Medicine Global Market Comparison Analysis

1.6.5 Orthopedic Regenerative Medicine Global Market Development Trend Analysis

Chapter Two Orthopedic Regenerative Medicine Up and Down Stream Industry Analysis

2.1 Upstream Raw Materials Analysis

2.1.1 Proportion of Manufacturing Cost

2.1.2 Manufacturing Cost Structure of Orthopedic Regenerative Medicine Analysis

2.2 Down Stream Market Analysis

2.2.1 Down Stream Market Analysis

2.2.2 Down Stream Demand Analysis

2.2.3 Down Stream Market Trend Analysis

Part II Asia Orthopedic Regenerative Medicine Industry (The Report Company Including the Below Listed But Not All)

Chapter Three Asia Orthopedic Regenerative Medicine Market Analysis

3.1 Asia Orthopedic Regenerative Medicine Product Development History

3.2 Asia Orthopedic Regenerative Medicine Competitive Landscape Analysis

3.3 Asia Orthopedic Regenerative Medicine Market Development Trend

Chapter Four 2016-2020 Asia Orthopedic Regenerative Medicine Productions Supply Sales Demand Market Status and Forecast

4.1 2016-2020 Orthopedic Regenerative Medicine Production Overview

4.2 2016-2020 Orthopedic Regenerative Medicine Production Market Share Analysis

4.3 2016-2020 Orthopedic Regenerative Medicine Demand Overview

4.4 2016-2020 Orthopedic Regenerative Medicine Supply Demand and Shortage

4.5 2016-2020 Orthopedic Regenerative Medicine Import Export Consumption

4.6 2016-2020 Orthopedic Regenerative Medicine Cost Price Production Value Gross Margin

Chapter Five Asia Orthopedic Regenerative Medicine Key Manufacturers Analysis

5.1 Company A

5.1.1 Company Profile

5.1.2 Product Picture and Specification

5.1.3 Product Application Analysis

5.1.4 Capacity Production Price Cost Production Value

5.1.5 Contact Information

5.2 Company B

5.2.1 Company Profile

5.2.2 Product Picture and Specification

5.2.3 Product Application Analysis

5.2.4 Capacity Production Price Cost Production Value

5.2.5 Contact Information

5.3 Company C

5.3.1 Company Profile

Continued

Download Free PDF Brochure:https://www.coherentmarketinsights.com/insight/request-pdf/3566

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email:[emailprotected]Web:https://www.coherentmarketinsights.com/

Read more:
Orthopedic Regenerative Medicine Market Study Based on Growth, Opportunities, Constraints and Development Factors for Next 5 Years - PRnews Leader

Global Regenerative Medicine market report offers a precise outline of the market that includes many aspects of market product definition, market segmentation, analysis, key developments, and existing vendors state of the business. These Regenerative Medicine industry documents include key players and geographical markets that have adopted vital methodologies for business developments and growth. The consumer trust in precise and proper Regenerative Medicine information structures that is employed for analysis of the business Report 2020 has the aim to deliver a complete analysis of the Regenerative Medicine market. The report could assist you in coming up with worthy growth methods and additionally aware and indurate challenges.

Perpetually increasing in the market, often rise in customers demands are the notable factors of growing and developing the business. Taking thought of each segments Regenerative Medicine market report is deliberate by creating each analysis of the market conditions worldwide. Examine the restraining Regenerative Medicine segments affecting the business in the coming future has been into consideration.

Get a Sample Copy of the Report at https://www.futuristicreports.com/request-sample/84632

Impact of COVID-19 on Regenerative Medicine Market

The report also contains the effect of the ongoing worldwide pandemic, i.e., COVID-19, on the Regenerative Medicine Market and what the future holds for it. It offers an analysis of the impacts of the epidemic on the international market. The epidemic has immediately interrupted the requirement and supply series. The report also assesses the economic effect on firms and monetary markets. Futuristic Reports has accumulated advice from several delegates of this business and has engaged from the secondary and primary research to extend the customers with strategies and data to combat industry struggles throughout and after the COVID-19 pandemic.

Global Regenerative Medicine Market: Competitive Landscape

(DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologies, Bellicum Pharmaceuticals)

Segment by Type, the Regenerative Medicine market is segmented into

Cell Therapy Tissue Engineering Biomaterial Other

Segment by Application, the Regenerative Medicine market is segmented into

Dermatology Cardiovascular CNS Orthopedic Others

To Understand How Covid-19 Impact Is Covered in This Report With additional Discount: https://www.futuristicreports.com/check-discount/84632

This report also splits the market by region:

United StatesCanadaMexicoBrazilAPACChinaJapanKorea

Key Questions Answered in The Report:

Market Report includes major TOC points1 Study Coverage1.1 Regenerative Medicine Product Introduction1.2 Market Segments1.3 Key Regenerative Medicine Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Regenerative Medicine Market Size Growth Rate by Type1.4.2 Measuring Smart Plug1.4.3 Regular Smart Plug1.4.4 Remote Control Smart Plug1.4.5 Other1.5 Market by Application1.5.1 Global Regenerative Medicine Market Size Growth Rate by Application1.5.2 Home1.5.3 Commercial1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Regenerative Medicine Market Size, Estimates and Forecasts2.1.1 Global Regenerative Medicine Revenue 2016-20262.1.2 Global Regenerative Medicine Sales 2016-20262.2 Global Regenerative Medicine, Market Size by Producing Regions: 2016 VS 2020 VS 20262.3 Regenerative Medicine Historical Market Size by Region (2016-2020)2.3.1 Global Regenerative Medicine Retrospective Market Scenario in Sales by Region: 2016-20202.3.2 Global Regenerative Medicine Retrospective Market Scenario in Revenue by Region: 2016-20202.4 Regenerative Medicine Market Estimates and Projections by Region (2021-2026)2.4.1 Global Regenerative Medicine Sales Forecast by Region (2021-2026)2.4.2 Global Regenerative Medicine Revenue Forecast by Region (2021-2026)

3 Global Regenerative Medicine Competitor Landscape by Players3.1 Global Top Regenerative Medicine Sales by Manufacturers3.1.1 Global Regenerative Medicine Sales by Manufacturers (2016-2020)3.1.2 Global Regenerative Medicine Sales Market Share by Manufacturers (2016-2020)3.2 Global Regenerative Medicine Manufacturers by Revenue3.2.1 Global Regenerative Medicine Revenue by Manufacturers (2016-2020)3.2.2 Global Regenerative Medicine Revenue Share by Manufacturers (2016-2020)3.2.3 Global Regenerative Medicine Market Concentration Ratio (CR5 and HHI) (2016-2020)3.2.4 Global Top 10 and Top 5 Companies by Regenerative Medicine Revenue in 20193.2.5 Global Regenerative Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Global Regenerative Medicine Price by Manufacturers3.4 Global Regenerative Medicine Manufacturing Base Distribution, Product Types3.4.1 Regenerative Medicine Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Regenerative Medicine Product Type3.4.3 Date of International Manufacturers Enter into Regenerative Medicine Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2016-2026)4.1 Global Regenerative Medicine Market Size by Type (2016-2020)4.1.1 Global Regenerative Medicine Sales by Type (2016-2020)4.1.2 Global Regenerative Medicine Revenue by Type (2016-2020)4.1.3 Regenerative Medicine Average Selling Price (ASP) by Type (2016-2026)4.2 Global Regenerative Medicine Market Size Forecast by Type (2021-2026)4.2.1 Global Regenerative Medicine Sales Forecast by Type (2021-2026)4.2.2 Global Regenerative Medicine Revenue Forecast by Type (2021-2026)4.2.3 Regenerative Medicine Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Regenerative Medicine Market Share by Price Tier (2016-2020): Low-End, Mid-Range, and High-End

5 Market Size by Application (2016-2026)5.1 Global Regenerative Medicine Market Size by Application (2016-2020)5.1.1 Global Regenerative Medicine Sales by Application (2016-2020)5.1.2 Global Regenerative Medicine Revenue by Application (2016-2020)5.1.3 Regenerative Medicine Price by Application (2016-2020)5.2 Regenerative Medicine Market Size Forecast by Application (2021-2026)5.2.1 Global Regenerative Medicine Sales Forecast by Application (2021-2026)5.2.2 Global Regenerative Medicine Revenue Forecast by Application (2021-2026)5.2.3 Global Regenerative Medicine Price Forecast by Application (2021-2026)

..Continued

Inquire or Share Your Questions If Any before the Purchasing This Report https://www.futuristicreports.com/send-an-enquiry/84632

Our Other Reports:

Global Semiconductor Photoresist Stripping Market Research Report

Global Cerebral Oximeters Market Research Report

Polyethylene Market in World Outlook, Dynamics and Forecast, Covid-19 Impact by 2026 | Futuristic Reports

Global Facial Erythema Therapies Market 2020 Competitive Landscape, Trends and Opportunities

Futuristic Reports

Name: Mark RiveraTel: +1-408-520-9037Email: [emailprotected]

Go here to read the rest:
Regenerative Medicine Market Size, Growth, Analysis Of Key- players Types And Application, Outlook, Covid-19 Impact by 2026 | Futuristic Reports - The...

In a recent clinical trial for an immune cell therapy for lymphoma, 62% of patients experienced complete cancer clearance in spite of the fact that some of them were on their 5th line of treatment. Stem cell therapies have the potential to enact more of these paradigm-shifting treatments. Proposition 14 will continue to advance these therapies and bring them to full development as available cures.

The vision of stem cell therapy is that a physician can just as easily grab an IV bag full of therapeutic cells as they might draw a drug into a syringe. Conceived through Proposition 71 in 2004, the California Institute for Regenerative Medicine (CIRM) serves as a vehicle to support all aspects of stem cell research. Medical progress requires not just well-designed clinical studies but also a well-trained workforce, educated at the intersection of stem cell biology, engineering, and chemistry.

Since 2008, CIRM has supported the training of nearly 1300 Community College and California State University students for the emerging field of Regenerative Medicine through the Bridges to Stem Cell Research and Therapy Program. The Bridges Training Program has functioned as a pathway for first-generation and underrepresented students from Humboldt to San Diego, to all of the biomedical sectors startup and cell therapy companies, academic research institutes, graduate and medical school, and more. Exposure to hands-on labs, advanced seminar discussions, and a required paid internship fully prepares these students for entering the stem cell workforce. Over 80% of Bridges alumni have either advanced to graduate school or joined the biomedical workforce in industry or academic institutions. These Programs bring a greater return than the initial cost of training.

SPONSORED

Consider Vahid Hamzeinejad, a bright high school student, headed to UC Berkeley to begin his college career. Enter the Great Recession; Vahid found himself back at home, working non-stop to help keep his parents restaurant afloat. Not giving up on his commitment to an education, he enrolled at the College of the Canyons. After completing an Associates degree, Vahid transferred to Cal Poly, hoping to join the Bridges Program. After receiving the Bridges core training, Vahid started his internship at ViaCyte, where he continues to work today, as a critical member of the team supporting ViaCytes clinical development of a functional cure for diabetes. The nearly $30 billion that California currently spends on diabetes treatments could be significantly reduced, in no small part due to the efforts of a student that cost taxpayers $36,000 to educate. That is before considering the benefit to patients quality of life that would occur by replacing insulin pumps, glucose monitors, and constant vigilance with a stem-cell-derived tissue that regulates blood sugar levels biologically making and secreting its own insulin.

Passing Proposition 14 will enable this and other unparalleled treatments for diabetes, heart disease, cancer, and neurological disorders.

Signed,

Robert Kam and the CIRM Bridges Program

SPONSORED

Continue reading here:
CIRM Bridges to Stem Cell Research & Therapy The Bridge to Everywhere (in biomedicine) OP-ED - The Silicon Valley Voice

InvestorPlace

In late September, a U.S. House vote to remove marijuana from the federal Controlled Substances Act was delayed until after the presidential election. If the House remains controlled by Democrats, industry analysts expect the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to potentially pass before the end of 2020. Then, it would be up to the Senate to possibly take a similar action. Today, we will look at three marijuana stocks to buy with decriminalization in the agenda.Canada is the first and only G7 nation to have legalized cannabis nationwide. In the U.S., at the federal level, marijuana is illegal and remains a Schedule I drug. Legal status varies at the state level. However, Democratic vice president nominee Kamala Harris has recently said marijuana would be decriminalized at the federal level under a Biden administration.2018 saw excessive speculation in marijuana stocks. Yet since 2019, a wide range of issues have affected the cannabis industry. Recreational cannabis sales in Canada hit significant headwinds and never reached the levels investors hoped. Although revenue improved for some companies, they have yet to become profitable. And cash burn remains concerning. As a result, most marijuana stocks have been on a roller coaster ride and hit new lows. Put another way, the bubble has burst.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAccording to recent research led by Douglas Berman of Ohio State University, the COVID-19 pandemic has both introduced tremendous new challenges for the cannabis industry and exacerbated long-standing difficulties for businesses in this arena.7 Value Stocks to Buy in an Overvalued MarketNonetheless, with difficulties usually come new opportunities while industry leaders and innovations may appear. With that information, here are three marijuana stocks that could benefit from U.S. developments at the federal level:Constellation Brands(NYSE:STZ)ETFMG Alternative Harvest ETF(NYSEARCA:MJ)GW Pharma(NASDAQ:GWPH)Marijuana Stocks: Constellation Brands(STZ)Source: ShinoStock / Shutterstock.comConstellation Brands is best known as a leading producer and marketer of alcoholic beverages. It holds a large portfolio of beer, wine and distilled spirits brands. Several of those well-recognized brands include Corona, Modelo, Robert Mondavi, Svedka vodka, Casa Noble tequila and High West whiskey. It is one the fastest-growing large consumer packaged goods companies stateside. Outside the U.S., it has operations in Italy, Mexico and New Zealand.The Victor, New York-based group is on our list of marijuana stocks because in 2018, it took a large stake in Ontario, Canada-based Canopy Growth(NYSE:CGC), one of the leading Canadian marijuana producers. STZs 38%-stake in CGC means the latter now has considerable managerial and financial backing.So far, this equity stake in Canopy Growth has been an earnings drag for Constellation Brands, and it will likely remain so in the near future. However, any potential improvement in the outlook of the pot sector in Canada and the U.S. could easily benefit STZ stock. Therefore, this indirect play on CGC could be a less risky approach for many investors.Year-to-date, STZ stock is down about 1.5%. However, that metric tells only half the story. Since the lows hit in early spring, the stock is up about 80%. The current forward price-earnings and price-sales ratios stand at at 20.88 and 4.78 respectively. Wed look to buy the the dips in price, especially if there is a decline toward the $175 level.ETFMG Alternative Harvest ETF (MJ)Source: ShutterstockThe ETFMG Alternative Harvest ETF offers exposure to Canadian cannabis producers as well as a number of firms with exposure to the industry, albeit indirectly. Thus the fund could be appropriate for long-term investors who are interested in the pot sector, but would like to have access to a diverse range of companies.MJ, which has 37 holdings, tracks the Prime Alternative Harvest index. Canopy Growth, Cronos (NASDAQ:CRON), and Tilray (NASDAQ:TLRY) top the list of holdings. Top-10 names make up around half of net assets, which stand around $550 million. The ETF was launched in 2015.7 Value Stocks to Buy in an Overvalued MarketSo far this year, the fund is down more than 30% and hit an all-time low in March. Since 2019, MJ has lost considerable value, driven by the industrys weakness and poor earnings by most pot companies. These stocks tend to be very choppy when their quarterly earnings are due. Given the volatility in the sector, long-term investors should be ready for large short-term price fluctuations in the fund. The sector is risky, but MJs diversification makes it safer than many alternatives.GW Pharma (GWPH)Source: ShutterstockOur final marijuana stock is the cannabis-focused biotech GW Pharma. According to a recent report by the United Nations, Britain is the biggest producer and exporter of legal cannabis in the world. And almost all of the exports are in a single drug, i.e., Sativex, produced by the UK-based GW Pharma. It is used to treat spasms in multiple sclerosis patients.Earlier in the year, the U.S. Drug Enforcement Administration also descheduled Epidiolex, another one of the companys products. As a result, it is no longer listed as a controlled substance stateside. In August, the U.S. Food and Drug Administration approved it to treat seizures in tuberous sclerosis complex.GW is also one of MJs largest holding, accounting for 6.41% of its assets. GWPH stock could be an alternative way to get exposure to the cannabis industry. Year-to-date, the shares are down around 8%. A potential decline toward $90 or below would improve the safety margin for long-term investors.On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article.TezcanGecgil has worked in investment management for over two decades in the U.S. and U.K. In addition to formal higher education in the field, she has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Her passion is for options trading based on technical analysis of fundamentally strong companies. She especially enjoys setting up weekly covered calls for income generation. She also publisheseducationalarticles on long-term investing.More From InvestorPlaceForget The Election Pick These Stocks for the Win in 2021Why Everyone Is Investing in 5G All WRONGAmericas #1 Stock Picker Reveals His Next 1,000% WinnerRevolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 CompanyThe post 3 Marijuana Stocks to Buy With Decriminalization on the Table appeared first on InvestorPlace.

Read more from the original source:
Former NFL Players Show Interest in Regenerative Medicine and Cell Therapies - Yahoo Finance

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Regenerative Medicine Market.

Trusted Business Insights presents an updated and Latest Study on Regenerative Medicine Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Regenerative Medicine Market during the forecast period.It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

We have updated Regenerative Medicine Market with respect to COVID-19 Business Impact.Inquire before buying

This report focuses on the Regenerative Medicine market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Regenerative Medicine market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Regenerative Medicine Market: Segment Analysis

The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Regenerative Medicine Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Regenerative Medicine Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.List of Companies Profiled

Report Coverage

The potential to directly alter human genes was first recognized nearly more than 50 years ago. Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals. Regenerative medicine also comprises of therapeutic tissue engineering and biomaterials -engineered substances used in medical applications to supplement or replace a natural body function. The increased number of the clinical trials and the use of the regenerative medicine for the development of the medicine to treat chronic diseases are some of the factors propelling the regenerative medicine market trends.

The report provides qualitative and quantitative insights on the regenerative medicine industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segments include type, application, distribution channel, and geography. On the basis of the type, the market is segmented into cell therapy, gene therapy, tissue engineering and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology and others. On the basis of distribution channel, the regenerative medicine market is segmented into hospitals, clinics and others. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the regenerative medicine market report comprises analysis of the industry dynamics and competitive landscape. Various key insights provided in the report are prevalence and incidence of diabetes by key countries, advancements in insulin delivery devices, recent industry developments such as mergers & acquisitions, pricing analysis, technological advancements, and key industry trends.

SEGMENTATION

By Product

By Application

By Distribution Channel

By Geography

Key Industry Developments

In September 2020, Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility provides end-to-end research and development capabilities and will accelerate Takedas efforts to develop next-generation cell therapies, initially focused on oncology with the potential to expand into other therapeutic areas.

The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U., and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world.

Takedas Cell Therapy Translational Engine (CTTE) connects clinical translational science, product design, development, and manufacturing through each phase of research, development, and commercialization. It provides bioengineering, chemistry, manufacturing, and control (CMC), data management, analytical, and clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease.

In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah.In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair defects reconstruction in a one-step procedure.

 

Looking for more? Check out our repository for all available reports on Regenerative Medicine Market in related sectors.

Quick Read Table of Contents of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Original post:
Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By...

Gosselies, Belgium, 12 October 2020, 7am CEST BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announce that CEO, Miguel Forte, MD, PhD will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12-16. Miguel Forte will also chair the session The European Regulatory Environment for ATMPs Should we expect more or less regulation? with the participation of panelists from the European Organization for Rare Diseases (EURORDIS), the European Medicines Agency (EMA) and the European Commission.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day virtual conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes over 100 panelists and featured speakers taking part in 20 in-depth sessions covering all aspects of cell and gene therapy commercialization. Companies presentations will be available to view on-demand throughout the entirety of the conference

Please visit http://www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Kaitlyn Dupont at kdupont@alliancerm.org.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid - a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0)71 12 10 00investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries:BepublicCatherine HaquenneTel: +32 (0)497 75 63 56catherine@bepublic.be

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: +33 (0)1 44 71 94 94bone@newcap.eu

For US Media and Investor Enquiries:LHA Investor RelationsYvonne BriggsTel: +1 310 691 7100ybriggs@lhai.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Continue reading here:
Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa - GlobeNewswire

Immuno-oncology and CAR T cells energized the field of regenerative medicine, but for cell and gene to deliver on their promises, new, disruptive technologies and new modes of operation are needed. Specifically, that entails improving manufacturing to control variables and thus ensure product consistency, and maturing the regulatory environment to improve predictability.

Manufacturing cells is not like manufacturing small molecules, Brian Culley, CEO of Lineage Cell Therapeutics, told BioSpace. For cell therapy products to mature into real products that deliver on the promises of 10 years ago, they must be scalable which drives affordability and they must solve their purity issues.

On the clinical side, cell and gene therapies must find places where small molecules, antibodies or other traditional approaches may not be the best option.

For example, The era of transplant medicine is unfolding before us, Culley said. Because of the transplant component, cell therapy may enable changes the body never could do alone.

Lineage is addressing dry AMD and spinal cord injuries with two of its therapeutics.

Our approach is fundamentally different from traditional approaches. We replace the entire cell rather than modulate a pathway. There is a rational hypothesis where cell therapy can win, but first we need to fix the operational hurdles, Culley said.

To address the manufacturing challenges, Culley said, We work only with allogeneic approaches. For us, not being patient-specific is a huge advantage.

Not long ago, the industry was focused on 3D manufacturing in bioreactors.

Were beyond that, Culley said. For our dry AMD product, we can manufacture 5 billion retinal cells in a three liter bioreactor. The advantage is that the cells exist in a very homogenous space and are 99% pure.

As a result, they are more affordable and can be harvested with little manipulation.

Manual manipulation affects gene expression, he pointed out, so minimizing that, as well as the vast quantities of plastics typically required, results in a more controlled process and a more consistent product.

Additionally, Lineage introduced a thaw and inject formulation, so the cell therapy can be thawed in a water bath, loaded into a chamber and injected, all within a few minutes. Traditional dose administration requires washing, plating and reconstituting the cells the before they are administered to a patient.

Getting rid of the prior day dose prep is one example of the maturation of the field, which we are deploying today to help usher in a new branch of medicine, Culley said.

At Lineage, were tackling problems that largely were intractable. For dry AMD, theres nothing approved by the FDA. No one know why the retinal cells die off, so we manufacture brand new retinal cells (OpRegen) and implant them, Culley said. Were seeing very encouraging clinical signs, including the first-ever case of retinal restoration.

Retinal cells compose a thin layer in the back of the eye, Culley explained.

They start to die off in one spot, and that area grows outward. When we inject our manufactured cells where the old ones died, weve seen the damaged area shrink and the architecture in previously damage areas completely restored, Culley said. Weve treated 20 patients for dry AMD in, ostensibly, safety trials, but you cant help but notice efficacy when a patient reads five more lines on an eye chart. Its hard to imagine our intervention wasnt responsible for that, especially when humans cant regenerate retinal tissue.

The spinal injury program (OPC1) may represent an even greater breakthrough. As with dry AMD, there is no FDA-approved therapy.

We manufacture oligodendrocytes and transport them into the spinal cord, to help produce the myelin coating for axons, he told BioSpace. Because of the oligodendrocytes, the axons grow, become myelinated, and begin to function. Small molecule and antibody therapies havent been able to do that.

So far, 25 people have been treated in a Phase I/II trial. Culley reported cases in which a quadriplegic man, after OPC1 therapy, is now typing 30 to 40 words per minute, and another who now can throw a baseball. Its not unusual for patients who initially were completely paralyzed to now schedule their treatments around college classes, Culley said.

Humans can have varying degrees of recovery from spinal cord injury, but these are higher than we would expect, Culley said.

Other cell and gene companies are advancing solutions, too.

Many companies with induced pluripotent stem cells (iPSCs) are trying to figure out how to get scalability, purity, and reproducibility to work for them. Its not a quick fix, he said.

One of the challenges is balancing the clinical and manufacturing aspects of development.

If you have a technology thats not yet commercially viable, but you have clinical evidence, its tempting to focus on the clinical side, Culley said.

Too many companies do that, and then find their candidate must be reworked for scale up. Therefore, consider scale up and manufacturing early.

Theres a need for balance at a more granular level, too. For example, he asked, How many release criteria do you need? Just because you know a cell expresses a certain surface marker, does that add to your process? Ive seen companies ruined by trying to be perfect, and others by rushing headlong, seeing evidence where evidence doesnt exist.

As Lineage matures its processes to support larger clinical trials, the greatest challenges have been time It takes 30 to 40 days to grow cells, Culley said and regulatory uncertainty. Often, there is no regulatory precedence so there are holes to be addressed. For example, cell and gene therapies sometimes have a delivery component such as a scaffold or delivery encapsulation technology that also must be considered. Real-time regulatory feedback isnt available, so you proceed, presuming that what youre doing will be acceptable to regulators.

The FDA recognizes that new, disruptive technologies and approaches are being used, and must be used, for cell and gene therapy to reach patients.

The FDA is responsive and is trying to push guidance out, Culley said, but it takes time.

Visit link:
Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation - BioSpace

Woolly worm race champion to predict winter weather this upcoming seasonNews / 8 hours ago

Hard Rock International, Bristol Chamber of Commerce host job information session for proposed casinoNews / 8 hours ago

Hundreds attend 'Trump Train Parade' in Sullivan County SaturdayNews / 8 hours ago

60th annual Southeastern Autorama returns to ErwinNews / 8 hours ago

Medical cannabis processor Dharma Pharma opens to patients in Bristol, VirginiaNews / 8 hours ago

The Volunteer Bus: Give back, Go Vols!News / 2 days ago

UPDATE: Police identify 3 dead after Saturday morning shootingNews / 8 hours ago

Trump Train Parade to go from Bristol to KingsportNews / 1 day ago

Hard Rock executives hold event for women and young professionals ahead of Bristol casino referendumNews / 1 day ago

Court TV interviewed Anslee Daniel regarding Evelyn Boswell case Friday nightNews / 1 day ago

Ballad leader: Fresh spike in COVID deaths likely four to six weeks awayNews / 1 day ago

Tennessee leaders to make adjustments to teacher accountabilityNews / 2 days ago

Continued here:
Woolly worm race champion to predict winter weather this upcoming season - WJHL-TV News Channel 11

As health sciences researchers conduct clinical trials to develop safe and effective therapies and vaccines for COVID-19, two nontrial pre-approval access pathways expanded access and right-to-try are becoming more widely-known to the general public.

A study published in Regenerative Medicine written by University of Minnesota Associate Professor Leigh Turner, Simon Fraser University Professor Jeremy Snyder, and New York University Assistant Professor Alison Bateman-House suggests thatmost patients engaged in online crowdfunding and seeking nontrial preapproval access to investigational medical products obtain them using the expanded access regulatory pathway rather than through what is known as the right-to-try.

The federal Right To Try (RTT) Act became law in 2018. It allows for individuals with life-threatening diseases to access investigational medical products if they:

Supporters, including President Trump, promote the right-to-try option as an important pathway for obtaining access to investigational medical products, said Turner, who is with the U of Ms Center for Bioethics. To date, however, few individuals appear to be obtaining access to such products on a right-to-try basis. Right-to-try has been promoted as a faster and less bureaucratic alternative to expanded access.

However, our research findings suggest that when it comes to crowdfunding campaigns on GoFundMe, references to right-to-try often reflect a poor understanding of nontrial preapproval access. In reality, at least according to the crowdfunding campaigns we examined, expanded access is the route by which individuals more commonly access investigational products outside clinical trials.

Expanded access, while also providing access to investigational medical products provided outside clinical trial context, differs significantly from the right-to-try pathway in that it requires FDA and institutional review board (IRB)oversight. The FDA and the IRB review submitted requests and decide if an investigational medical product should be provided on an expanded access basis. President Trump, for example, recently obtained access to an investigational product for COVID-19 a monoclonal antibody cocktail on an expanded access basis.

The experimental interventions allowed under the RTT Act and through an expanded access basis are not commonly covered by insurers. As a result, many individuals engage in online crowdfunding activity to cover the often substantial costs associated with accessing investigational interventions provided outside clinical trials.

Turner and his co-authors identified 79 GoFundMe campaigns referencing right-to-try and 115 campaigns referencing expanded access between April 2019 and April 2020. These campaigns also discussed seeking experimental medical interventions in the U.S.

When restricting analysis to campaigns initiated in 2018 and later, which is around the time the RTT Act was made into law, the researchers identified:

Through this study, researchers found that:

It is important to note that the campaigns on GoFundMe list donation goals and funds received but they may not accurately reflect costs associated with seeking access to investigational medical products pursued via expanded access pathway or a right-to-try option. Furthermore, data collected on crowdfunding sites does not necessarily reflect experiences of individuals who seek access to investigational medical products administered outside clinical trials but do not engage in crowdfunding activities.

Acknowledging these limitations, the study does suggest that, in practice, expanded access provides meaningful access to investigational medical products whereas right-to-try is more rhetorical slogan than practical option.

Read more:
Crowdfunding campaigns seeking donations supporting the use of investigational medical products provided via expanded access or 'right-to-try'...

This report also researches and evaluates the impact of Covid-19 outbreak on the Japan Regenerative Medicine Products industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Japan Regenerative Medicine Products and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Global Japan Regenerative Medicine Products Market Overview:

The research report, titled [Global Japan Regenerative Medicine Products Market 2020 by Company, Regions, Type and Application, Forecast to 2025], presents a detailed analysis of the drivers and restraints impacting the overall market. Analysts have studied the key trends defining the trajectory of the market. The research report also includes an assessment of the achievements made by the players in the global Japan Regenerative Medicine Products market so far. It also notes the key trends in the market that are likely to be lucrative. The research report aims to provide an unbiased and a comprehensive outlook of the global Japan Regenerative Medicine Products market to the readers.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2785605&source=atm

Global Japan Regenerative Medicine Products Market: Segmentation

For clearer understanding of the global Japan Regenerative Medicine Products market, analysts have segmented the market. The segmentation has been done on the basis of application, technology, and users. Each segment has been further explained with the help of graphs figures. This breakdown of the market gives the readers an objective view of the global Japan Regenerative Medicine Products market, which is essential to make sound investments.

Segment by Type, the Regenerative Medicine Products market is segmented intoCell TherapyTissue EngineeringBiomaterialOthers

Segment by Application, the Regenerative Medicine Products market is segmented intoDermatologyCardiovascularCNSOrthopedicOthers

Regional and Country-level AnalysisThe Regenerative Medicine Products market is analysed and market size information is provided by regions (countries).The key regions covered in the Regenerative Medicine Products market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

To understand the changing political scenario, analysts have regionally segmented the market. This gives an overview of the political and socio-economic status of the regions that is expected to impact the market dynamic.

Global Japan Regenerative Medicine Products Market: Research Methodology

To begin with, the analysis has been put together using primary and secondary research methodologies. The information has been authenticated by market expert through valuable commentary. Research analysts have also conducted exhaustive interviews with market-relevant questions to collate this research report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2785605&source=atm

Global Japan Regenerative Medicine Products Market: Competitive Rivalry

The research report also studied the key players operating in the global Japan Regenerative Medicine Products market. It has evaluated and elucidated the research and development statuses of these companies, their financial outlooks, and their expansion plans for the forecast period. In addition, the research report also includes the list of strategic initiatives that clearly explain the achievements of the companies in the recent past.

Competitive Landscape and Regenerative Medicine Products Market Share AnalysisRegenerative Medicine Products market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Regenerative Medicine Products business, the date to enter into the Regenerative Medicine Products market, Regenerative Medicine Products product introduction, recent developments, etc.The major vendors covered:AcelityDePuy SynthesMedtronicZimmerBiometStrykerMiMedx GroupOrganogenesisUniQureCellular Dynamics InternationalOsiris TherapeuticsVcanbioGamida CellGolden MeditechCytori TherapeuticsCelgeneVericel CorporationGuanhao BiotechMesoblastStemcell TechnologesBellicum Pharmaceuticals

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2785605&licType=S&source=atm

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Japan Regenerative Medicine Products market

Chapter 2: Evaluating the leading manufacturers of the global Japan Regenerative Medicine Products market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Japan Regenerative Medicine Products market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Contact Us:

marketresearchhub

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About marketresearchhub

marketresearchhub is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

See original here:
Research report covers the Japan Regenerative Medicine Products Market Forecasts and Growth, 2019-2025 - Eurowire

Oct. 16, 2020 13:00 UTC

PRINCETON, N.J.--(BUSINESS WIRE)-- The Geistlich Medical business unit of Geistlich Pharma AG, a family owned, Swiss based global leader in regenerative solutions is proud to announce that the General Services Administration (GSA) has added Geistlich Derma-Gide Advanced Wound Matrix to the Federal Supply Schedule (FSS). Geistlich Pharma focuses on a wide variety of clinical indications.

The GSA award will pave the way for physicians and staff of Veterans Administration facilities to utilize Geistlich Derma-Gide for the management of hard to heal wounds. The product is FDA cleared for a wide variety of indications, including diabetic foot ulcers, venous leg ulcers, surgical wounds, and first/second degree burns (among others).

Advanced wound care for those in need

Geistlich Medical has partnered with Recon-Supply, a Service-Disabled Veteran-Owned Small Business owned by Marine Corps veteran Stephen Clark and his wife Katy Clark. It was important to Geistlich Medical to partner with a SDVOSB in order to support and honor those that have served in the US Military, says Geistlich CEO Paul Note. We found a great organization in Recon-Supply and look forward to serving the Veterans Administration facilities as they treat those in need of advanced wound care. All nine of the Geistlich Derma-Gide sizes are a part of the FSS so that physicians and their staff have full access to the portfolio of products available to the broader healthcare market.

Novel second-generation xenograft

Geistlich Derma-Gide Advanced Wound Matrix is a novel second generation xenograft product that features an advanced 4D design: Dual-sourced, highly refined, bi-layered, and structurally optimized. It has demonstrated a 90% closure rate in its first 10 patient observational study recently published in International Wound Journal1. A larger prospective, randomized clinical trial is currently underway, with interim results to be published in late 2020.

1 Armstrong, DG, Orgill, DP, Galiano, RD, et al. An observational pilot study using a purified reconstituted bilayer matrix to treat nonhealing diabetic foot ulcers. Int Wound J. 2020; 17: 966 973.

About Geistlich Pharma

Geistlich Pharma has existed since 1851 and is family-owned. It specializes in the regeneration of bone, cartilage and tissue. More than 700 employees worldwide work for Geistlich in the area of regenerative medicine. With its twelve affiliates and 60 distribution partners, Geistlichs medical devices and medicinal products reach around 90 markets worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201016005406/en/

Go here to see the original:
Geistlich Derma-Gide Added to the General Services Administration's Federal Supply Schedule - BioSpace

Market Study Report, LLC recently added a report on Regenerative Medicine market that delivers a holistic view on industry valuations, market size, profit estimations, SWOT analysis and regional landscape of the market. In addition, the report points out key challenges and growth opportunities, while examining the current competitive standings of key players in during the forecasted timeline.

The research report on Regenerative Medicine market report provides a detailed analysis of this business landscape. The document analyses various market dynamics such as the opportunities and factors which drive the market growth. The market is poised to generate notable revenue and display a remunerative growth rate during the analysis timeframe, cites the report.

Request a sample Report of Regenerative Medicine Market at:https://www.marketstudyreport.com/request-a-sample/2440816?utm_source=technoweekly.com&utm_medium=SK

Additionally, the report assesses the existing market competition trends and elaborates on various risk factors which may hamper the growth of the Regenerative Medicine market during the analysis timeframe.

The document also highlights the impact of COVID-19 pandemic on the growth of Regenerative Medicine market.

Additional takeaways of the Regenerative Medicine market report:

Details of the regional analysis of the Regenerative Medicine market:

Ask for Discount on Regenerative Medicine Market Report at:https://www.marketstudyreport.com/check-for-discount/2440816?utm_source=technoweekly.com&utm_medium=SK

Table of Contents:

The key questions answered in the report:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-regenerative-medicine-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Viral Vectors and Plasmid DNA Manufacturing Market 2020 by Company, Regions, Type and Application, Forecast to 2025Read More: https://www.marketstudyreport.com/reports/global-viral-vectors-and-plasmid-dna-manufacturing-market-2020-by-company-regions-type-and-application-forecast-to-2025

2. Global Flu Vaccine Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Read More: https://www.marketstudyreport.com/reports/global-flu-vaccine-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Related Report : https://www.marketwatch.com/press-release/at-302-cagr-deep-packet-inspection-dpi-market-size-poised-to-cross-usd-36-billion-by-2026-2020-10-15

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read the original here:
Regenerative Medicine Market to Witness a Pronounce Growth During 2020 to 2025 - TechnoWeekly

HAIFA, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today announced that it has received clearance from the safety committee of an investigator initiated Phase I/II study to move forward with patient enrollment for cohort II. The study will evaluate PLX-PAD cells in the treatment of steroid-refractory chronic graft vs. host disease (GvHD) and is led by Principal Investigator Prof. Ron Ram, Director of the Hematology Blood and Marrow Stem Cell Transplantation Unit at Tel Aviv Sourasky Medical Center, Ichilov Hospital, Israel. Prof. Ram and his research staff are responsible for the design and implementation of the study at Sourasky Medical Center.

GvHD is a severe complication in patients who have undergone an allogeneic hematopoietic cell transplantation (HCT) and is a major cause of morbidity and mortality in these patients in which the donated stem cells identify the recipient's body as foreign and attack it. The chronic form of GvHD (cGvHD) usually appears later than 100 days post-transplant.

Cohort I included 6 patients treated with 2 injections of 150 million cells, a week apart. At the 3-month follow up, interim safety results concluded that PLX-PAD cells were safe and that no treatment related side effects were reported. Efficacy results demonstrated that 4 out of the 6 patients reported improvement in symptoms that translated into a reduction in the severity of cGvHD with notable reduction in the required steroid doses for part of the patients. Based on these results, the study was approved to commence enrollment of 14 patients in cohort II to be treated with 4 injections of 150 million cells.

Prof. Ram of Ichilov Hospital commented, From our experience in having treated 6 patients in the study to date, we have so far found no negative side effects from the use of the PLX-PAD cells in the treatment of steroid-refractory cGvHD. Patients with significant GvHD skin disorders previously unresponsive to multiple types of therapy showed remarkable response. Responses were also observed for severe mouth ulcers which prevented patients from eating solid foods. This resulted in a major improvement of quality of life and tapering of steroid doses."

Pluristem is committed to contributing to the wellbeing and quality of life of our patients. cGvHD is an indication where we see a significant need to enhance the current course of treatment for this life-threatening condition among patients undergoing bone marrow transplants. The preliminary results from cohort I of this Phase I/II study, and prior preclinical data, both indicate that PLX-PAD cells may potentially treat cGvHD patients and mitigate symptoms. We are very pleased to cooperate with Prof. Ram and Sourasky Medical Center, and we place a high importance in examining PLX-PAD for this indication, stated Pluristem CEO and President, Yaky Yanay.

About cGvHDChronic graft-versus-host disease (cGvHD) remains a common and potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (HCT). The 2-year cumulative incidence of chronic GvHD requiring systemic treatment is 30% to 40% by National Institutes of Health criteria1. The hematopoietic stem cell transplants are used to treat bone marrow failure resulting from treatment of some blood or bone marrow cancers as well as other hematologic failures, such as aplastic anemia, which are not related to cancer. The donated cells identify the recipients body as foreign and attack it as a result. While acute GvHD usually appears in the first 100 days after a transplant, and in specific body systems, chronic GvHD can occur at any time (even several years) after a transplant, and may manifest in many parts of the body such as: skin, mouth, eyes, liver, intestines, lungs and joints. Long term immunosuppression is given to try to prevent or treat cGvHD. Since this treatment suppresses the immune system for a very long time, patients are at high risk of infections, and are prescribed multiple medications to try to address this major risk.

About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor StatementThis press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the patient enrollment for cohort II for its Phase I/II study of its PLX-PAD cells, the implication from the results of the first patient cohort in the study, the belief that GvHD is an indication that has a significant need for enhanced treatments among patients undergoing bone marrow transplants and that the preliminary results from cohort I of the study, and the prior preclinical data, indicate that PLX-PAD cells may potentially treat chronic GvHD patients and mitigate symptoms. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact:

Dana RubinDirector of Investor Relations972-74-7107194danar@pluristem.com

_________________________________

1 Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015 Jan 22;125(4):606-15. doi: 10.1182/blood-2014-08-551994. Epub 2014 Nov 14. PMID: 25398933; PMCID: PMC4304105., https://pubmed.ncbi.nlm.nih.gov/25398933/

View post:
Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease...